Tin tức & Cập nhật
Xem bài viết Dược
Xem
ED patients who do not respond to PDE5I may benefit from topical alprostadil–PDE5i combo
For men with erectile dysfunction (ED) who show a lack of response to oral phosphodiesterase type 5 inhibitors (PDE5Is), combination therapy with topical alprostadil plus PDE5Is seems favourable, producing greater improvements in sexual function without compromising safety compared with topical alprostadil alone, as shown in a study.
Tislelizumab produces long-term benefits in relapsed, refractory classical Hodgkin lymphoma
Treatment with the antiprogrammed cell death protein 1 (anti–PD-1) monoclonal antibody tislelizumab yields high response rates in relapsed or refractory classical Hodgkin's lymphoma, with a similar toxicity profile as other anti–PD-1 therapies, as shown in the extended results of a phase II trial.
Empagliflozin benefits similar between MRA users, nonusers
In patients with heart failure (HF) and preserved ejection fraction, treatment with empagliflozin delivers comparable benefits in reducing first hospitalization for HF or cardiovascular death (primary outcome) between users and nonusers of mineralocorticoid receptor antagonists (MRA), reports a study.
DOACs, LMWH prevent VTE, but increase bleeding, in major noncardiac surgery
Use of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) appears to reduce venous thromboembolism (VTE) in major noncardiac surgery compared with no active treatment, a study has shown. However, it may also increase major bleeding to a similar extent.